Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at ...
Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 35,100 calls trading, 5x expected, and implied vol increasing almost 42 points to 161.96%. 10/24 weekly 7 calls and 10/24 weekly 7 ...
Pinker's new book reveals how recursive mentalizing—thinking about thinking—may be the hidden engine of human life, from ...
Investors in Recursion Pharmaceuticals Inc (Symbol: RXRX) saw new options begin trading this week, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Diebold Nixdorf isn't as well-known as BigBear.ai, but it could have better growth prospects. Recursion Pharmaceuticals' AI drug discovery gives it a shot at growing larger than BigBear.ai. Will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback